Affordable Access

Targeting protein kinases for the development of anti-inflammatory drugs

Elsevier Ltd
Publication Date
DOI: 10.1016/
  • Biology
  • Medicine
  • Pharmacology


In recent years, protein kinases have become the pharmaceutical industry's most studied class of drug target, and some 10 protein kinase inhibitors have so far been approved for the treatment of cancer. However, whether safe drugs that modulate protein kinase activities can also be developed for the treatment of chronic diseases, where they may need to be taken for decades, is an issue that is still unresolved. A number of compounds that inhibit the p38α MAPK have entered clinical trials for the treatment of rheumatoid arthritis and psoriasis, but side effects have prevented their progression to Phase III clinical trials. Here I briefly review the potential problems in targeting p38 MAPK and discuss other protein kinases that regulate the innate immune system, such as Tpl2, MAPKAP-K2/3, MSK1/2 and IRAK4, which may be better targets for the treatment of chronic inflammatory diseases, and NIK, which is an attractive target for the treatment of multiple myeloma, a late stage B-cell malignancy.

There are no comments yet on this publication. Be the first to share your thoughts.


Seen <100 times

More articles like this

Mitogen activated protein kinases as targets for d...

on Annals of the Rheumatic Diseas... November 2004

Targeting the protein kinases for anti-cancer ther...

on The Korean Journal of Hematolo... Sep 01, 2012

Protein kinases: From targets to anti-cancer drugs

on Annales Pharmaceutiques França... Jan 01, 2010
More articles like this..